EGFR and non-small cell lung carcinoma: Over the past two decades, small molecules, primarily tyrosine kinase inhibitors (TKIs), targeting mutations or translocations in ALK, ROS, NTRK, MET, EGFR, KRAS, and BRAF have been clinically approved for NSCLC patients, resulting in complete or partial responses in most cases [3, 4, 5].